...
首页> 外文期刊>Journal of clinical laboratory analysis. >CD62P and P10 as predictive markers for assessing the efficacy of hemodialysis in treating end-stage renal disease
【24h】

CD62P and P10 as predictive markers for assessing the efficacy of hemodialysis in treating end-stage renal disease

机译:CD62P和P10作为评估血液透析在治疗末期肾病中的疗效的预测标志物

获取原文
获取原文并翻译 | 示例

摘要

Background CD62P is a platelet alpha-granule membrane protein, and P10 is a platelet membrane glycoprotein thrombospondin. To better understand the effects of hemodialysis (HD), we have conducted this study to investigate CD62P and P10 in assessing the efficacy of HD in treating patients with end-stage renal disease (ESRD). Methods The case group consisted of 111 patients suffering ESRD treated with regular HD and the control group enrolled 117 healthy subjects. Before and after HD treatment, a series of parameters were observed, based on which, CD62P and P10 levels were detected in the patients in two groups before and after HD therapy. The correlation analysis analyzed the correlations of CD62P and P10 markers with serum creatinine (Scr), blood urea nitrogen (BUN), and subjective score; and logistic regression analysis was performed to reveal factors affecting the efficacy of HD. Results BUN, Scr, serum phosphorus, intact parathyroid hormone (iPTH), fibrinogen, and beta 2-microglobulin (beta 2-MG) decreased while hemoglobin, albumin, and activated partial thromboplastin time increased in the patients suffering ESRD; patients presented with improvements in subjective symptoms and an increase in dry weight. CD62P and P10 levels were lower in post-treatment patients. CD62P and P10 positively correlated with Scr, BUN and subjective score; post-treatment CD62P and P10 levels, BUN, hemoglobin, albumin, triglyceride, iPTH, beta 2-MG, and fibrinogen were correlated with the efficacy of HD. Conclusion CD62P and P10 might be correlated to the efficacy of HD in treating ESRD, in turn providing predictive markers for assessing the ability of HD in treating ESRD.
机译:背景技术CD62P是血小板α-颗粒膜蛋白,P10是血小板膜糖蛋白血栓状蛋白。为了更好地了解血液透析(HD)的影响,我们已经进行了该研究,以研究CD62P和P10评估HD治疗患有终末期肾病(ESRD)的患者的疗效。方法案例组由患有常规HD治疗的111名患者组成,对照组注册了117名健康科目。在HD处理之前和之后,观察到一系列参数,根据其中,在HD疗法之前和之后在两组中检测到其中CD62P和P10水平。相关分析分析了CD62P和P10标记与血清肌酐(SCR),血尿尿素氮(BUN)和主观评分的相关性;对逻辑回归分析进行了揭示影响HD疗效的因素。结果BUN,SCR,血清磷,完整的甲状旁腺激素(IPTH),纤维蛋白原和β2-微球蛋白(β2-MG)在血红蛋白,白蛋白和活化的部分血栓形成蛋白患者中患有ESRD的患者增加;患者随着主观症状的改善和干重的增加。治疗后患者CD62P和P10水平较低。 CD62P和P10与SCR,BUN和主观分数正相关;治疗后CD62P和P10水平,BUN,血红蛋白,白蛋白,甘油三酯,IPTH,β2-Mg和纤维蛋白原与HD的功效相关。结论CD62P和P10可能与HD治疗ESRD治疗ESRD的疗效相关,用于评估HD治疗ESRD的能力的预测标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号